Maged Shenouda

Maged Shenouda previously served as CFO and Executive Vice President of Corporate Development for AzurRx BioPharma, Inc. Prior to his tenure at AzurRx, Mr. Shenouda was Senior Vice President and Head of Business Development and Licensing at Retrophin, Inc. Before this, Mr. Shenouda spent the bulk of his career on Wall Street as an equity research analyst. He held senior level positions at UBS, JP Morgan and Stifel Nicolaus, covering a broad range of small and large capitalization biotechnology companies. Mr. Shenouda started his sell-side equity research career at Citigroup and Bear Stearns where his coverage universe focused on U.S and European pharmaceutical companies. Before entering Wall Street, he was a management consultant with PricewaterhouseCoopers Pharmaceutical Consulting practice and also spent time in pharmaceutical sales, having worked as a hospital representative and managed care specialist for Abbott Laboratories Pharmaceutical Products Division. He earned a B.S. in Pharmacy from St. John's University and is a registered pharmacist in New Jersey and California. He also received an M.B.A from Rutgers Graduate School of Management.